Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 11 May

Sophia Mavridis
May 11, 2022

Morning Bell 10 May

Paulina Peters
May 10, 2022

Morning Bell 9 May

Sophia Mavridis
May 9, 2022

Weekly Wrap 6 May

Sophia Mavridis
May 6, 2022

Morning Bell 5 May

Paulina Peters
May 5, 2022

Morning Bell 4 May

Sophia Mavridis
May 4, 2022

Morning Bell 3 May

Paulina Peters
May 3, 2022

Morning Bell 2 May

Sophia Mavridis
May 2, 2022

Weekly Wrap 29 April

Sophia Mavridis
April 29, 2022

Morning Bell 28 April

Paulina Peters
April 28, 2022

Morning Bell 27 April

Sophia Mavridis
April 27, 2022

Morning Bell 26 April

Paulina Peters
April 26, 2022